Skip to main content

Table 2 Correlation between overexpression of ezrin, ezrin Thr-567 and ezrin Tyr-353 proteins and clinical parameters of NSCLC

From: Prognostic implications of ezrin and phosphorylated ezrin expression in non-small cell lung cancer

  Ezrin EzrinThr-567 EzrinTyr-353
Parameters No. of cases n(%) P n(%) P n(%) P
Gender    0.062   0.45   0.230
  Male 112 75 (67.0) 69 (61.6) 77 (68.8)
  Female 38 19 (50.0) 26 (68.4) 30 (78.9)
Age    0.077   0.642   0.364
  60 99 67 (67.7) 64 (64.6) 73 (73.7)
  <60 51 27 (52.9) 31 (60.8) 34 (66.7)
Tumor size    0.283   .791   0.620
  T1-2 119 72 (60.5) 76 (63.9) 86 (72.3)
  T3-4 31 22 (71.0) 19 (61.3) 21 (67.7)
Stage    0.000**   .031*   0.000**
  I-II 98 51 (52.0) 56 (57.1) 59 (60.2)
  III-IV 52 43 (82.7) 39 (75.0) 48 (92.3)
Differentiation    0.007 a **   0.002 a **   0.006 a **
  Well 34 17 (50.0) 16 (47.1) 21 (61.8)
  Moderate 89 54 (60.7) 55 (61.8) 61 (68.5)
  Poor 27 23 (85.2) 24 (88.9) 25 (92.6)
LN metastasis    0.318   0.002**   0.578
  Negative 96 63 (65.6) 52 (54.2) 67 (69.8)
  Positive 54 31 (57.4) 43 (79.6) 40 (74.1)
  1. *P < 0.05; **P < 0.01; a: Poorly vs Well and moderately differentiated tumors.